Tilray Soars on Marijuana Rescheduling Hopes

Tilray Brands (NASDAQ:TLRY) stock experienced a notable surge, with shares climbing roughly 10% in early Thursday trading near $8.68, building on a 14% rise the previous day. This rally is fueled by intensifying speculation that the current administration is preparing to reclassify marijuana to a less dangerous drug category. Such a regulatory shift is a significant development that cannabis investors have anticipated for years.

Recent reports suggest the administration is expected to reclassify marijuana as a Schedule III drug. This move would reportedly ease federal barriers to cannabis research and potentially unlock tax treatment advantages for cannabis operators. Tilray Brands CEO Irwin D. Simon has repeatedly emphasized the transformative impact of rescheduling, noting it would advance medical cannabis research, physician involvement, and patient access in the U.S.

Despite the positive sentiment, the current stock movement remains speculative. The company's Q3 FY26 financial report on April 1 showed revenues of $206.73 million, surpassing consensus estimates, though adjusted EPS of $0.02 missed expectations. International cannabis revenue saw a substantial year-over-year increase of 73%, reaching $24.12 million.

While cannabis peers like Canopy Growth and Aurora Cannabis typically react to rescheduling headlines, prediction markets indicate caution. Contracts for marijuana rescheduling by December 31, 2026, are priced with probabilities as low as 39%. Investors are closely monitoring for official confirmation from the DEA or DOJ, with a pending DEA status update in July and potential litigation adding layers of uncertainty to the unfolding situation.